Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000149" target="_blank" >RIV/26475821:_____/13:#0000149 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/13:00067728 RIV/00669806:_____/13:10140092
Result on the web
<a href="http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=3086&category_id=102&option=com_virtuemart" target="_blank" >http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=3086&category_id=102&option=com_virtuemart</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2013_004" target="_blank" >10.4149/neo_2013_004</a>

Result language
angličtina
Original language name
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Original language description
Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor used in treatment of advanced NSCLC. Patients harboring EGFR or KRAS mutations represent minority of all patients in caucasian population and there is no available predictor for apredominant group of patients harboring the wild-type EGFR and wild-type KRAS genes. Skin rash is the most frequent manifestation of cutaneous toxicity of erlotinib. Rash is associated with a good therapeutic response. We aimed at the evaluation of rashas a predictor of therapeutic effect of erlotinib in patients harboring the wild-type EGFR and KRAS wild-type genes and to assess its possible usage in a clinical practice.Totally 184 patients with advanced stage NSCLC (IIIB, IV) harboring the wild-typeEGFR and wild-type KRAS genes were analysed. Comparison of ORR, PFS and OS according to the occurrence of rash was performed. Rash is strongly associated with better survival and ORR in patients harboring wild-type EGFR and wild-type KRA
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Project
<a href="/en/project/NR9087" target="_blank" >NR9087: Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)